• Prescribing Information
  • Patient Information
  • Patient Site
  • Phase III Study Primary Endpoint*
    Phase III Study Secondary Endpoints*
    Phase III Study: Other Endpoints*
    Infant Study: Exploratory Endpoint**

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    EUCRISA Safety Data

    Safety profile established in 4 studies, including pivotal and open-label safety extension studies, and an open-label infant safety study

    AN ENDPOINT IN AN OPEN-LABEL SAFETY EXTENSION STUDY

    Percentage of patients who did not receive rescue therapy4

    In an open-label safety extension study, 517 patients were cycled on or off therapy in 4-week intervals as needed for 48 weeks.3 Rescue therapy was prescribed and recorded at the investigator’s judgment to treat intolerable atopic dermatitis, defined as the worsening of disease that significantly affected the patient’s normal function or invited responsive behavior that could be harmful.*,3

    In an open-label safety extension study, 517 patients were cycled on or off therapy in 4-week intervals as needed for 48 weeks.3 Rescue therapy was prescribed and recorded at the investigator’s judgment to treat intolerable atopic dermatitis, defined as the worsening of disease that significantly affected the patient’s normal function or invited responsive behavior that could be harmful.*,3
    ​​​​​​​
    Includes patients who received rescue therapy more than once
    ​​​​​​​3 patients received both TCS and TCI for rescue therapy.
    TCS=topical corticosteroid; TCI = topical calcineurin inhibitor.
    396 patients followed for 6 months, 271 patients followed for 12 months.4
    This study reflects information from a study where patients enrolled were 2 years and older.
    References
    1. EUCRISA® (crisaborole) Full Prescribing Information. April 2020.
    2. Data on File. Pfizer Inc., New York, NY.
    3. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.
    4. Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641-649.e5.
    5. Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020. 21:275-284.

    If babies could talk, what would they tell you?

    Hear JP with mild-to-moderate AD explain what EUCRISA means to him and other babies like him
    ​​​​​​​
    Not an actual patient

    Watch JP's story

    ** This is an optional area where footnotes can live.

    3 to <24 Month Study Data

    Learn more about 28-day, open-label, single-arm, safety study in 3 to <24 month old patients5

    See data

    ** This is an optional area where footnotes can live.

    Card Header

    The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

    Card CTA

    ** This is an optional area where footnotes can live.

    Infant Safety Study Design

    Learn more about Infant Safety Study design and baseline demographics

    Learn more

    ** This is an optional area where footnotes can live.

    Exploratory Pruritus Endpoint

    Find out more about the time to relief in pruritus as found in the Phase III study's exploratory endpoint

    Learn more

    ** This is an optional area where footnotes can live.

    Learn how the first and only nonsteroidal topical PDE4 inhibitor works within the skin1

    The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4

    Learn more

    ** This is an optional area where footnotes can live.

    Copay Cards

    *Eligible patients pay as little as $10​​​​​​

    Terms and Conditions apply​​​​​​

    ​​​​* Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.

    Download Copay cards

    ** This is an optional area where footnotes can live.

    Savings & Support Program

    A savings and support program for your patients to help them with their access to EUCRISA

    See resources

    ** This is an optional area where footnotes can live.

    Order Samples

    Register or sign in to check availability and request samples.

    Order now

    ** This is an optional area where footnotes can live.

    Contraindications

    EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

    Warnings and Precautions

    Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

    Adverse Reactions

    The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

    Please see Full Prescribing Information and Patient Information

    EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    INDICATION

    EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.